Novo Nordisk Balances Amazon Access and Generic Onslaught as Pipeline Decision Looms

Novo Nordisk's stock is squeezed between a landmark Amazon Pharmacy distribution deal and pricing erosion from Indian generics after patent expiry, despite strong oral Wegovy sales and a promising CagriSema pipeline.

Novo Nordisk finds itself caught between a surge in distribution firepower and a creeping erosion of its pricing power. The Danish drugmaker’s shares closed Friday at €38.56 in Frankfurt, down 1.82% on the day but up 11.72% over the past month. That near-term bounce masks a deeper malaise: the stock has shed roughly 13.7% since the start of the year and sits 35% below where it traded twelve months ago, far from the 52-week peak of over €70.

The two forces pulling the stock in opposite directions are playing out simultaneously. On one side, a landmark partnership with Amazon Pharmacy is dramatically widening access to oral semaglutide. The e-commerce giant has begun offering the Ozempic tablet — available in three dosages for adults with type 2 diabetes — with same-day delivery now live in nearly 3,000 US cities. By the end of 2026, Amazon aims to cover approximately 4,500 locations. The move cuts reliance on traditional pharmacy chains and complements existing access programs through Weight Watchers and GoodRx.

On the other side, India is proving to be a textbook case of what happens when blockbuster patents expire. Novo Nordisk lost exclusivity for semaglutide in the country in March, triggering an immediate influx of cheap generics from at least a dozen local manufacturers, including Sun Pharma, Dr. Reddy’s, Cipla, and Zydus Lifesciences. The company responded by slashing list prices: Ozempic fell 38% and Wegovy dropped 48%, to roughly $60 per unit. Despite the cuts, combined sales of the diabetes and obesity brands rose 40% in April to 32,000 units, though the broader market grew 56% as cheaper copies ate into the branded share.

The Indian dynamic is widely viewed as a preview of the global patent cliff. Already, Canada has approved its first semaglutide generics, and analysts expect similar moves in other emerging markets.

At the heart of Novo Nordisk’s US business, the oral Wegovy pill is the clear bright spot. More than 2 million prescriptions have been written since its January launch, making it the strongest GLP-1 debut in American history. In the first full week alone, prescriptions topped 18,000. The brand now commands 65% of all new US scripts for oral GLP-1 drugs. First-quarter revenue from the Wegovy tablet reached 2.26 billion Danish kroner, comfortably beating Jefferies’ consensus estimate.

The real wild card remains the late-stage pipeline. Novo Nordisk filed CagriSema — a fixed-dose combination of cagrilintide and semaglutide — with the FDA in December 2025, with a decision expected by end of 2026. In the Phase 3 REDEFINE 1 study, patients lost an average of 23% of their body weight over 68 weeks, versus 2.3% on placebo. A separate analysis put the figure at 22.7%. But the drug missed a key non-inferiority target against Eli Lilly’s tirzepatide, and a high-dose Phase 3 study is planned for the second half of this year.

Separately, the company is advancing cagrilintide as a monotherapy. A subanalysis showed roughly 12% weight loss at 68 weeks via a biological pathway distinct from GLP-1; a broader Phase 3 program called RENEW is expected to confirm those results.

Investor sentiment remains cautious. Citigroup recently lifted its price target to 290 Danish kroner but kept a “Neutral” rating, while Bernstein continues to recommend selling the stock. For 2026, Novo Nordisk has modestly improved its guidance but still expects declining revenue and operating profit at constant exchange rates.

All eyes now turn to three milestones: the Amazon rollout’s pace, incoming generic data from Asian markets, and the FDA’s verdict on CagriSema. The next scheduled catalyst is the half-year report on August 5, 2026, which will reveal whether near-term access wins can offset the gathering storm from cheap competition.